Biocon Receives DCGI Nod to Market Abraxane (India)
This article was originally published in PharmAsia News
Executive Summary
Biotech company Biocon Ltd. has received approval from the Drug Controller General of India to market Abraxane, its breast cancer drug. Biocon recently concluded a licensing agreement with U.S.-based Abraxis BioScience Inc. for the commercialization of Abraxane in India. Biocon has completed the required formalities to divest its enzymes business vertical to Novozymes South Asia Pvt Ltd, a wholly-owned subsidiary of Denmark-based Novozymes for Rs453.79 crore. Biocon will use the post tax proceeds of this divestment to strategically focus on its core bio-pharmaceuticals business as well as consider key acquisition opportunities to move up the value chain. (Click here for more - May Require Free Registration
You may also be interested in...
Biden COVID-19 Plan Would Grow Domestic Manufacturing Base
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
People On The Move: Appointments At Sanofi, Enzymatica And Bayer
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
Trust, Innovation And Growth – Three Priorities For The Global Self-Care Industry In 2021
The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."
Need a specific report? 1000+ reports available
Buy Reports